Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes-Reference-Cited by-同舟云学术

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

Published:2024-08-08 Issue:1 Volume:15 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Venkadakrishnan Varadha Balaji^ORCID,Presser Adam G.,Singh Richa,Booker Matthew A.,Traphagen Nicole A.,Weng Kenny^ORCID,Voss Nathaniel C. E.,Mahadevan Navin R.,Mizuno Kei,Puca Loredana,Idahor Osasenaga,Ku Sheng-Yu^ORCID,Bakht Martin K.^ORCID,Borah Ashir A.^ORCID,Herbert Zachary T.,Tolstorukov Michael Y.^ORCID,Barbie David A.,Rickman David S.^ORCID,Brown Myles^ORCID,Beltran Himisha^ORCID

Funder

Prostate Cancer Foundation

U.S. Department of Defense

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41467-024-51156-5.pdf

Reference66 articles.

1. Quintanal-Villalonga, A. et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat. Rev. Clin. Oncol. 17, 360–371 (2020).

2. Beltran, H. et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin. Cancer Res. 25, 6916–6924 (2019).

3. Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492–2503 (2018).

4. Abida W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA. https://doi.org/10.1073/pnas.1902651116, https://www.ncbi.nlm.nih.gov/pubmed/31061129 (2019).

5. Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487–495 (2011).